Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Veriheal

MAY 26, 2022

In turn, cannabis advocates have struggled to properly educate the public with the limited amount of scientific evidence available. RoC also works to increase patients’ access to medical cannabis by helping U.S. states pass relevant legislation and educating doctors about the power of cannabis medicine.

Advocacy 96

Advocacy Patients Clinical Trials Education 96

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. Additional clinical trials underway in the U.S. Allowing people to be educated sets them up for a safe, enjoyable “trip.”.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. The millions of people afflicted with PTSD may soon have access to MDMA therapy, and we believe the millions suffering from TBI may experience similar relief in the future.”.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable, and accessible work environment. European Regulatory Lead Executive Summary. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We NPA’s mission is to ensure all Americans get the support they need to safely access psychedelic-assisted care. ABOUT MAYA.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

DECEMBER 9, 2021

Nue Life launched its proprietary nue.app on November 8 to increase access to psychedelic treatment as a catalyst for lasting change. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. For more information, please visit www.nue.life.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

JUNE 29, 2021

Synergetic Press and the Multidisciplinary Association for Psychedelic Science (MAPS) are pleased to announce they have entered into a copublishing relationship effective May 1, 2021 which will greatly expand the availability of education about psychedelics and psychedelic therapy. founder and executive director of MAPS.

Therapy 90

Therapy Research and Development Clinical Trials Education 90

TheAnswerPage

JANUARY 11, 2022

As the Editor-in-Chief of the medical education website called TheAnswerPage.com for nearly two decades, I have assessed multiple educational gaps in the healthcare community. Thus, an educational gap developed, creating a less than ideal situation for medical marijuana patients. So, why did this educational gap develop?

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Key Responsibilities. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Cannabis Law Report

APRIL 21, 2022

Commercialization & Patient Access · Any City, Any State, California. It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine and profiled on the front page of The New York Times. About MAPS Public Benefit Corporation (MAPS PBC).

Advocacy 52

Advocacy Therapy Clinical Trials Environment 52

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Cannabis Law Report

JULY 1, 2021

Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. POPLAR is the first academic initiative focused on psychedelics law and policy, positioned to be a global leader for research and education in this space. Background. The Project.

Law 59

Law Policy Research and Development Clinical Trials 59

Veriheal

AUGUST 31, 2020

At Veriheal, education and diversity are at the center of our core values. Choosing only 10 winners for the $10,000 in scholarships among the strong applications we received from multiple disciplines and concentrations in higher education—from students of all backgrounds and interests—was extremely difficult.

Research and Development 117

Research and Development Education Agriculture Patients 117

CannaTech

SEPTEMBER 16, 2018

Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. The Need for Cannabis Education Tailored to Patient and Doctor. Shedding Stigma and Promoting Patient Access. Education and Resources to Drive Medical Cannabis.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

JULY 28, 2021

We believe in diversity and inclusion of people of all backgrounds, genders, races, ethnicities, sexual orientations, educational backgrounds, military and veteran status,?religions, MAPS PBC strives to continually improve upon the supportive, equitable and accessible work environment. Experience working for a clinical study Sponsor.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

SpeedWeed

JULY 6, 2021

By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”. The project also intends to advance research into how psychedelics can heal trauma and how to ensure equitable access to these therapies.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2019

Current barriers to patient access to medicinal cannabis in Australia. On 14 November 2019, the Senate referred an inquiry into the current barriers to patient access to medicinal cannabis in Australia to the Senate Community Affairs References Committee for inquiry and report by 12 February 2020. Accessibility.

Clinical Trials 58

Clinical Trials Access Medicine Patients 58

MMJ Recs

DECEMBER 22, 2023

This shift can be attributed to increased access to information, a more liberal societal outlook, and a willingness to explore alternative healthcare options. These campaigns focus on dispelling myths, highlighting success stories, and educating the public about the science behind cannabis-based treatments.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. On Tuesday, January 24, several legislative bills were unveiled by the Japanese government.

Legalization 58

Legalization Marijuana Clinical Trials Seed-To-Sale 58

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Deputy General Counsel Executive Summary.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Veriheal

MAY 12, 2021

In light of such, and the fact that cancer is a common qualifying condition for cannabis, this research team took to expanding the available basic information on cannabis in the cancer population in order to provide clinical trial designers with better information needed for planned studies.

Patients 98

Patients Consumption Clinical Trials Education 98

Cannabis Law Report

AUGUST 21, 2019

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. Doctors don’t have any education, training, and they don’t understand, she said.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

AUGUST 3, 2021

ADCL’s solution includes the use of subcontractor CLEARED4’s health verification platform for appointments, sample tracking, and value-add services of campus access management. FDA) or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

AUGUST 19, 2019

Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government. This is at least due to the difficulty and cost involved in accessing a legal prescription. Patient access pathways.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

AUGUST 2, 2021

SAN DIEGO–(BUSINESS WIRE)– Radicle Science , a transformative healthtech B-corp validating natural products for the first time, announces the launch of the Radicle ACES (Advancing CBD Education and Science) study. Eric Schudiske, eric@s2spr.com.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Healer

MARCH 26, 2021

Seventeen of 19 pre-clinical studies provided “robust” evidence of the opioid-sparing effects of cannabinoids, but one of the nine clinical studies provided “very low-quality” evidence of such, according to the review. The researchers stressed the need for large, well-designed clinical trials.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

OCTOBER 12, 2021

Mary Hartnett, Director of Medical Services at Sarah Lawrence College, stated, “safeCircle was our choice given the convenience of its on-site sample collection process, access to high-sensitivity RT-PCR-based testing with rapid turnaround times, ability to scale with our needs, and capacity to ease our administrative burdens.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

MMJ Recs

JUNE 15, 2022

Located in Midtown, this clinic provides patients with easy access to their doctors – you can text, live chat, or book online for same-day appointments. Image by Hannah Busing on Unsplash : There are many well-renowned pain management clinics in New York City. There are also helpful patient reviews found online as well.

Patients 52

Patients Treatment Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 2, 2021

Under the approved recommendations, students applying for psilocybin training programs are required to provide a description of their educational background and a written statement explaining their commitment and interest in becoming a psilocybin facilitator. Training Administration Recommendations. Training Curriculum Recommendations.

Law 52

Law Programs Therapy Education 52

The Joint Blog

NOVEMBER 4, 2019

Many expressed a desire to receive additional education about cannabis in order to become better versed in the subject.” Healthcare providers play a critical role in facilitating patient access to medical cannabis. ” The full abstract of the study can be found below: Background.

Therapy 42

Therapy Clinical Trials Conditions Patients 42

Cannabis Law Report

SEPTEMBER 2, 2021

ADCL will serve as prime contractor with subcontractor CLEARED4’s health verification platform to be used for appointments, sample tracking, reporting, program management, and mobile access pass visibility. Food and Drug Administration (U.S.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is the largest national chain of ketamine infusion clinics in the United States and will add to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers in California and Arizona , cementing its position as the leading and largest health provider in the country.

Treatment 52

Treatment Media Research and Development Patients 52